MKI67 and neoplasm: Currently, Ki-67 expression is typically assessed using immunohistochemistry (IHC); however, this method faces two key challenges: its invasive nature (12), and the inability of a localized sample to represent the entire tumor, given NSCLC’s significant heterogeneity (13, 14).